Navigation Links
Gene therapy converts dead bone graft to new, living tissue

Researchers have created a way to transform the dead bone of a transplanted skeletal graft into living tissue in an experiment involving mice. The advance, which uses gene therapy to stimulate the body into treating the foreign splint as living bone, is a promising development for the thousands of cancer and trauma patients each year who suffer with fragile and failing bone grafts. The findings were posted online Feb. 13 and will appear in the March 1 issue of Nature Medicine.

The procedure, designed by a team led by Edward M. Schwarz, Ph.D., associate professor of orthopedics and of microbiology and immunology at the University of Rochester Medical Center, is intended to eventually aid people with various cancers or injuries whose treatment involves the replacement of large sections of bone. Cancers such as osteosarcoma, one of the most common types of bone cancers, or tumors that occur adjacent to bones, often must be treated by removing the diseased section of bone and replacing it with the only alternative available ?a donated section of comparable bone from a cadaver. The new splint of bone is then literally screwed into place, giving the patient most of the strength and support of the original bone. Bone, unlike any other tissue in the human body, can still perform one of its functions, structural support, even if all its cells are completely dead. A serious problem arises, however, when the bone wears over time.

"Everyday activities cause microscopic fractures in our bones," explains Schwarz. "Those fractures are normal and healthy, and our bones re-knit them constantly. But when the bone is dead, there is no healing, and those tiny fractures begin to accumulate until finally, perhaps in 10 years, the implanted section collapses, and more drastic surgery becomes necessary."

To make the transplanted bone more robust, Schwarz looked into the activity of the genes and proteins that govern its health. His team replaced sections of bones in
'"/>

Source:University of Rochester Medical Center


Page: 1 2 3 4

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
5. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
6. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
7. New therapy for HIV/AIDS eliminates needles and excessive toxicity
8. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
9. Gene therapy for Parkinsons disease moves forward in animals
10. Pulsating ultrasound enhances gene therapy for tumors
11. Antiretroviral therapy may prevent excess risk of some cancers in people with HIV
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene therapy converts dead bone graft new living tissue

(Date:8/18/2015)... 18, 2015  Navitas today announced that ... the Submission Content Management webinar scheduled on ... forum. Dedicated to the Implementation of Regulatory Submission ... for industry, vendors, health authorities, consultants and ... towards a standard method of implementing electronic ...
(Date:8/17/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Q4 2015. The new marketing campaign is being spearheaded ... Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ... in retail driven marketing and brand awareness and has ...
(Date:8/12/2015)... , August 12, 2015 ... of mobile payment innovation and advanced biometrics technology is ... the way consumers rely on using their credit cards, ... reinventing the future for payment services led by companies ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ), ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... demonstrated that morphine withdrawal complicates hepatitis C by suppressing ... Wang et al., Morphine withdrawal enhances hepatitis C virus ... The American Journal of Pathology and is accompanied by ... is common among intravenous drug users, with 70 to ...
... can result in two immune system disorders that ... severe infections, according to new findings reported in ... may lead to new diagnostic tests for these ... common variable immunodeficiency (CVID). Currently, doctors diagnose the ...
... a "time machine," assert Duke neuroscientists Catalin Buhusi and ... is essential to understanding all its functions. The brain's ... communicating, to orchestrating movement, to getting food, they said. ... Nature Reviews Neuroscience, Buhusi and Meck discuss the current ...
Cached Biology News:Hepatitis C complicated by morphine withdrawal 2Biologists Crack Genetic Code for Specialized Spider Silk 2Biologists Crack Genetic Code for Specialized Spider Silk 3What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 2What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 3What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 4
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
(Date:8/27/2015)... 27, 2015 GlassesOff (OTCBB: GLSO), a ... in the human vision system, announced today a partnership with ... Chris Paul to develop a new mobile app ... improve their real-life on-court performance. Vision is the ... is shooting a ball or blocking a pass. The critical ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... today that a second US laboratory is to open in Manhattan, Kansas in ... continued partnership and long-term growth of research and development through collaboration with researchers ...
(Date:8/26/2015)... Aug. 26, 2015  Platform therapeutic company Symic ... received a $1.5M Phase II SBIR grant from ... develop its therapeutic agent to reduce arteriovenous fistula ... end stage renal disease (ESRD) patients undergoing hemodialysis. ... of Diabetes and Digestive and Kidney Diseases (NIDDK), ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... QC, May 19 /PRNewswire-FirstCall/ - Neptune Technologies & ... its consolidated financial results for the fiscal year ... EBITDA(1) and first-time profitability for the three-month period ... amended their stock option plan. , Neptune reports ...
... Reprints NRx for the Force.com AppExchange saves time for ... process from within Salesforce CRMSANTA MONICA, Calif., May 19 ... announced the availability of Reprints NRx for ... the Force.com platform, Reprints NRx for the AppExchange is ...
... Cell Therapeutics, Inc. (the "Company" or "CTI") (Nasdaq and MTA: ... Auction" tender offer (the "Exchange Offer") to increase the total ... stock, no par value (the "Common Stock"), and cash for ... the following outstanding series of its convertible notes (the "Notes"):, ...
Cached Biology Technology:Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 2Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 3Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 4Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 5Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 2Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 3Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 2Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 3Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 4Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 5
... system uses the Adept CE 4100 high pressure ... UV/Visible detector for added flexibility and utra low ... alternative to a photodiode array detection and provides ... is required for method development and for monitoring ...
... is a new product number, created ... If showing no availability yet, please ... (E6152) or contact customer service for ... diam. 11.25 6.40 in. ...
... numbers of samples may be carried out using ... attention. System control and data processing is ... The elegant, powerful and very easy to ... 98 and 2000., The supplied detector is the ...
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
Biology Products: